Cargando…

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

Detalles Bibliográficos
Autores principales:	Fanotto, Valentina, Uccello, Mario, Pecora, Irene, Rimassa, Lorenza, Leone, Francesco, Rosati, Gerardo, Santini, Daniele, Giampieri, Riccardo, Di Donato, Samantha, Tomasello, Gianluca, Silvestris, Nicola, Pietrantonio, Filippo, Battaglin, Francesca, Avallone, Antonio, Scartozzi, Mario, Lutrino, Eufemia Stefania, Melisi, Davide, Antonuzzo, Lorenzo, Pellegrino, Antonio, Ferrari, Laura, Bordonaro, Roberto, Vivaldi, Caterina, Gerratana, Lorenzo, Bozzarelli, Silvia, Filippi, Roberto, Bilancia, Domenico, Russano, Marco, Aprile, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2018
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813760/ https://www.ncbi.nlm.nih.gov/pubmed/29449512 http://dx.doi.org/10.1634/theoncologist.2017-0158erratum

Ejemplares similares

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
por: Fanotto, Valentina, et al.
Publicado: (2016)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials
por: Rosati, Gerardo, et al.
Publicado: (2019)

Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice
por: Fanotto, Valentina, et al.
Publicado: (2023)

Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials
por: Aprile, Giuseppe, et al.
Publicado: (2015)

Molecular classifications of gastric cancers: Novel insights and possible future applications
por: Garattini, Silvio Ken, et al.
Publicado: (2017)

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
por: Aprile, Giuseppe, et al.
Publicado: (2015)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
por: Rimini, Margherita, et al.
Publicado: (2023)

Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
por: Rosati, Gerardo, et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
por: Balsano, Rita, et al.
Publicado: (2023)

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
por: Lutrino, Eufemia S., et al.
Publicado: (2019)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
por: Cinausero, Marika, et al.
Publicado: (2017)

Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
por: Del Prete, Michela, et al.
Publicado: (2015)

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)
por: Damato, Angela, et al.
Publicado: (2020)

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer
por: Fornaro, Lorenzo, et al.
Publicado: (2019)

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
por: Procaccio, Letizia, et al.
Publicado: (2023)

Cancer cachexia and chronic inflammation: an unbreakable bond
por: Macciò, Antonio, et al.
Publicado: (2023)

Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies
por: Cucciniello, Linda, et al.
Publicado: (2022)

Role of molecular genetics in the clinical management of cholangiocarcinoma
por: Normanno, N., et al.
Publicado: (2022)

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
por: D’Anzeo, Marco, et al.
Publicado: (2014)

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
por: Nappo, Floriana, et al.
Publicado: (2023)

Editorial: Cancer evolution: From biological insights to therapeutic opportunities
por: Davis, Andrew A., et al.
Publicado: (2022)

The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients
por: Basile, Debora, et al.
Publicado: (2019)

Topological, non-topological and instanton droplets driven by spin-transfer torque in materials with perpendicular magnetic anisotropy and Dzyaloshinskii–Moriya Interaction
por: Carpentieri, Mario, et al.
Publicado: (2015)

Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy
por: Casadei-Gardini, Andrea, et al.
Publicado: (2023)

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Napolitano, Stefania, et al.
Publicado: (2023)

Risk of Hepatocellular Carcinoma in Workers Exposed to Chemicals
por: Uccello, Mario, et al.
Publicado: (2012)

Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
por: Maccaroni, Elena, et al.
Publicado: (2015)

The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective
por: Malapelle, Umberto, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?
por: Vivaldi, Caterina, et al.
Publicado: (2020)

Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker
por: Pelizzari, Giacomo, et al.
Publicado: (2019)

Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma
por: Uccello, Mario, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_o7f2dmp27m86e1fsvahblsec9n